Ovid Therapeutics (OVID) Competitors

Ovid Therapeutics (NASDAQ:OVID) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership.

Do analysts recommend OVID or LFCR?

Ovid Therapeutics presently has a consensus price target of $3.10, indicating a potential upside of 148.00%. Lifecore Biomedical has a consensus price target of $8.00, indicating a potential upside of 4.99%. Given Ovid Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Ovid Therapeutics is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ovid Therapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.17
Lifecore Biomedical	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Is OVID or LFCR more profitable?

Lifecore Biomedical has a net margin of -31.70% compared to Ovid Therapeutics' net margin of -574.44%. Ovid Therapeutics' return on equity of -58.87% beat Lifecore Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ovid Therapeutics	-574.44%	-58.87%	-43.18%
Lifecore Biomedical	-31.70%	-846.51%	-13.03%

Do insiders and institutionals believe in OVID or LFCR?

72.2% of Ovid Therapeutics shares are owned by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are owned by institutional investors. 13.1% of Ovid Therapeutics shares are owned by insiders. Comparatively, 32.2% of Lifecore Biomedical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Which has higher valuation & earnings, OVID or LFCR?

Ovid Therapeutics has higher earnings, but lower revenue than Lifecore Biomedical. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Ovid Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ovid Therapeutics	$6.65M	13.36	-$26.43M	-$0.53	-2.36
Lifecore Biomedical	$128.87M	2.21	-$38.72M	-$1.31	-5.82

Which has more volatility and risk, OVID or LFCR?

Ovid Therapeutics has a beta of 0.2, meaning that its stock price is 80% less volatile than the S&P 500. Comparatively, Lifecore Biomedical has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500.

Does the media prefer OVID or LFCR?

In the previous week, Ovid Therapeutics had 5 more articles in the media than Lifecore Biomedical. MarketBeat recorded 7 mentions for Ovid Therapeutics and 2 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 1.30 beat Ovid Therapeutics' score of 0.85 indicating that Lifecore Biomedical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ovid Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lifecore Biomedical	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ovid Therapeutics beats Lifecore Biomedical on 10 of the 17 factors compared between the two stocks.